Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.

Nicoletta ColomboDomenica LorussoBradley J MonkBrian SlomovitzKosei HasegawaAngélica Nogueira-RodriguesMelissa ZaleChinyere E OkparaGianmaria BarresiJodi McKenzieVicky Makker

Published in: The oncologist (2023)

NCT03517449.

Keyphrases

endometrial cancer
advanced non small cell lung cancer
emergency department
adverse drug
epidermal growth factor receptor
tyrosine kinase
electronic health record